利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

731 条记录 (耗时 0.024 秒)

    Percutaneous absorption preparations of antidementia drugs
    5.
    发明授权
    Percutaneous absorption preparations of antidementia drugs 有权
    抗衰老药物的经皮吸收制剂

    公开(公告)号：US07858114B2

    公开(公告)日：2010-12-28

    申请号：US11797722

    申请日：2007-05-07

    申请人： Takeshi Ito

    发明人： Takeshi Ito

    IPC分类号： A61K31/55 ,  A61K31/473 ,  A61K31/445 ,  A61K31/13

    CPC分类号： A61K9/7084 ,  A61K31/13 ,  A61K31/165 ,  A61K31/435 ,  A61K31/445 ,  A61K31/553 ,  Y10S514/946 ,  Y10S514/947

    摘要： Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug.

    摘要翻译： 公开了能够长时间稳定地施用抗药性的经皮吸收制剂。 更具体地，用作皮肤上的膏药的抗药性药物的经皮吸收制剂至少包含粘贴层，中间膜和药物储存层，其从贴在皮肤上的一侧开始，其中药物储存层 至少包含抗痴呆药物，胺化聚合物，多元醇和一种或多种羧酸酯，所述中间膜使得抗痴呆药物能够受控地渗透到皮肤侧，所述粘附层能够抹去经皮吸收 在皮肤上制备，并且对抗药物是可渗透的。

    Topical application for treating toenail fungus
    9.
    发明授权
    Topical application for treating toenail fungus 失效
    局部应用治疗趾甲真菌

    公开(公告)号：US07288533B2

    公开(公告)日：2007-10-30

    申请号：US11025726

    申请日：2004-12-29

    申请人： James Edward Brehove

    发明人： James Edward Brehove

    IPC分类号： A01N55/08 ,  A61K8/00 ,  C07F5/02

    CPC分类号： A61K31/69 ,  A61K9/7015 ,  Y10S514/936 ,  Y10S514/947

    摘要： A topical applications is used to treat and prevent the spread of nail infections or onychomycosis caused by bacteria, fungi and other pathogens. The topical application has a composition that comprises, as an active ingredient, at least one species selected from the group consisting of 2,2′-(alkyldioxy) bis-(alkyl-1,3,2-dioxaborinane) and 2,2′-oxybis(alkyl-1,3,2-dioxaborinane). More specifically, the composition comprises, as an active ingredient, at least one member selected from the group consisting of 2,2′-(1-methyltrimethylene dioxy) bis-(4-methyl-1,3,2-dioxaborinane) and 2,2′-oxybis (4,4,6-trimethyl-1,3,2-dioxaborinane).

    摘要翻译： 使用局部应用来治疗和预防由细菌，真菌和其他病原体引起的指甲感染或甲真菌病的扩散。 局部应用具有包含作为活性成分的至少一种选自2,2' - （烷基二氧基）双 - （烷基-1,3,2-二氧杂硼烷）和2,2' （烷基-1,3,2-二氧杂硼烷）。 更具体地说，该组合物包含作为活性成分的至少一种选自2,2' - （1-甲基三亚甲基二氧基）双 - （4-甲基-1,3,2-二氧杂硼烷）和2 ，2'-氧双（4,4,6-三甲基-1,3,2-二氧杂硼烷）。

    Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
    10.
    发明授权
    Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof 有权
    用于药物活性剂的快速和无刺激性透皮递送的组合物和用于配制这种组合物的方法和其递送

    公开(公告)号：US07267829B2

    公开(公告)日：2007-09-11

    申请号：US10831416

    申请日：2004-04-23

    申请人： Kenneth B Kirby ,  Berno Pettersson

    发明人： Kenneth B Kirby ,  Berno Pettersson

    IPC分类号： A61F13/00 ,  A61L15/16

    CPC分类号： A61K9/0014 ,  A61K36/232 ,  A61K36/324 ,  A61K36/53 ,  A61K36/74 ,  A61K36/752 ,  A61K47/10 ,  A61K47/12 ,  Y10S514/946 ,  Y10S514/947 ,  A61K2300/00

    摘要： A transdermal delivery system (TDS)for use in treatment of living bodies may be applied as an open (liquid, gel) or closed (patch) article. The TDS is composed of a particular active agent which dictates an associated selection of certain solvents, solvent modifiers, solute modifiers and skin stabilizers with which the medicament forms a true solution that rapidly crosses the skin barrier. The associated selection of the particular solvents, solvent modifiers, solute modifiers and skin stabilizers is based on a balancing of the molecular properties of all the components against the molecular properties of all the components plus the particular active agent. The TDS may also include a source of cellular energy to induce CAMP or cGMP. The TDS improves delivery of active agents having a molecular weight greater than 340 Daltons and increases dosage above 0.25 mg/day for such active agents.

    摘要翻译： 用于治疗活体的透皮递送系统（TDS）可以作为开放（液体，凝胶）或封闭（补片）制品应用。 TDS由特定的活性剂组成，该活性剂决定某些溶剂，溶剂改性剂，溶质改性剂和皮肤稳定剂的相关选择，药物形成快速穿过皮肤屏障的真正溶液。 特定溶剂，溶剂改性剂，溶质改性剂和皮肤稳定剂的相关选择是基于所有组分的分子性质与所有组分加上特定活性剂的分子性质的平衡。 TDS还可以包括诱导CAMP或cGMP的细胞能量来源。 TDS改善了分子量大于340道尔顿的活性剂的递送，并且增加了对于这种活性剂的剂量高于0.25mg /天。